BUSINESS BRIEFING / PHARMACEUTICALS
Times Wire Reports
AstraZeneca and Merck & Co. said they would jointly develop a pair of drugs meant to hit cancer with a one-two punch, part of a growing trend of combination cancer treatments.
The companies, two of the world’s biggest drug makers, said they would combine efforts with Merck’s MK-2206 and AstraZeneca’s AZD6244, both of which are still in very early development.
